Scilex Holding Company Comprehensive Income
Scilex Holding Company (SCLX) reported Comprehensive Income of -$115.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$115.16M.
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$44.02M.
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$39.94M.
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$260.79M.
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$370.85M.
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$66.49M.
- Scilex Holding Company comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$114.33M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$115.16M 10-Q · filed 2026-08-14 | -$159.18M 10-Q · filed 2026-08-14 | -$199.11M derived: sum of 3 quarters · filed 2026-08-14 | -$459.90M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$44.02M 10-Q · filed 2026-05-20 | -$83.95M derived: sum of 2 quarters · filed 2026-05-20 | -$344.74M derived: sum of 3 quarters · filed 2026-05-20 | -$430.80M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$39.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$300.73M derived: sum of 2 quarters · filed 2026-04-10 | -$386.79M derived: sum of 3 quarters · filed 2026-08-14 | -$370.85M 10-K · filed 2026-04-10 | ||
| 2025-09-30 | -$260.79M 10-Q · filed 2025-11-14 | -$346.85M derived: sum of 2 quarters · filed 2026-08-14 | -$330.92M 10-Q · filed 2025-11-14 | -$378.08M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$86.06M 10-Q · filed 2026-08-14 | -$44.05M 10-Q · filed 2025-08-13 | -$112.14M 10-Q · filed 2026-08-14 | -$70.13M 10-Q · filed 2025-08-13 | -$117.30M derived: sum of 3 quarters · filed 2026-08-14 | -$118.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$26.08M 10-Q · filed 2026-05-20 | -$31.23M derived: sum of 2 quarters · filed 2026-05-20 | -$32.46M derived: sum of 3 quarters · filed 2026-05-20 | -$68.19M derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2024-12-31 | -$5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$6.38M derived: sum of 2 quarters · filed 2026-04-10 | -$42.11M derived: sum of 3 quarters · filed 2026-04-10 | -$66.49M 10-K · filed 2026-04-10 | ||
| 2024-09-30 | -$1.23M 10-Q · filed 2025-11-14 | -$36.96M derived: sum of 2 quarters · filed 2025-11-14 | -$61.34M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$35.73M 10-Q · filed 2025-08-13 | -$60.11M 10-Q · filed 2025-08-13 | ||||
| 2023-12-31 | -$21.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$56.93M derived: sum of 2 quarters · filed 2025-03-31 | -$83.58M derived: sum of 3 quarters · filed 2025-03-31 | -$114.33M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$35.53M 10-Q · filed 2025-01-17 | -$62.18M derived: sum of 2 quarters · filed 2025-01-17 | -$92.93M 10-Q · filed 2025-01-17 | |||
| 2023-06-30 | -$26.65M 10-Q · filed 2024-08-13 | -$57.40M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |